Modality
mRNA
MOA
CDK4/6i
Target
MALT1
Pathway
RAS/MAPK
Prostate CaAS
Development Pipeline
Preclinical
~Jun 2024
→ ~Sep 2025
Phase 1
Dec 2025
→ Jun 2025
Phase 1Current
NCT06865309
2,486 pts·Prostate Ca
2025-12→2025-06·Active
2,486 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0610mo agoInterim· Prostate Ca
Trial Timeline
Q3Q4
P1
Active
Catalysts
Interim
2025-06-06 · 10mo ago
Prostate Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06865309 | Phase 1 | Prostate Ca | Active | 2486 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |